---
title: "Structure and epitope mapping of the conformational anti‑tau antibody DC11"
id: "biorxiv-13-structure-and-epitope-mapping-of-the-conformational-anti-tau-antibody-dc11"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-13-structure-and-epitope-mapping-of-the-conformational-anti-tau-antibody-dc11"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.09.01.748351v1?rss=1"
published_at: "2026-09-02T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Structure and epitope mapping of the conformational anti‑tau antibody DC11
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-13-structure-and-epitope-mapping-of-the-conformational-anti-tau-antibody-dc11
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.09.01.748351v1?rss=1)
- **Published At:** 2026-09-02T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The conformational antibody **DC11** distinguishes between physiological full‑length **tau** proteins and misfolded, truncated tau variants. - DC11 was previously observed to **catalyze in vitro tau aggregation**, indicating it recognizes a pre‑aggregation tau conformation. - The authors crystallized the **Fab** fragment of DC11 and deposited structural data (PDB reference provided in the source). - Binding of DC11 to truncated tau proteins was characterized using **ELISA**, **NMR**, and **crosslinking mass spectrometry**; these orthogonal methods defined the antibody–antigen interaction in solution and on peptides. - A structural model of the DC11–truncated tau complex was generated by docking conformations of tau321–391, obtained from coarse‑grained molecular dynamics simulations, into the antibody paratope. - The combined approach integrates high‑resolution Fab structure, biochemical binding assays, solution NMR, crosslinking data, and computational docking to infer the epitope and binding mode of a conformational anti‑tau antibody. - The work links DC11’s conformational specificity to tau species associated with misfolding and aggregation, supporting a role for antibody recognition in modulating tau aggregation pathways. - Specific experimental parameters, numeric binding constants, and detailed residue‑level contact lists were not fully reported in the source abstract and would require consultation of the full preprint or supplementary files.
## Clinical Analysis & Structured Key Points
Structure and epitope mapping of the conformational anti tau antibody DC11 | bioRxiv Skip to main content New Results Structure and epitope mapping of the conformational anti tau antibody DC11 View ORCID Profile Stefana Njemoga , View ORCID Profile Leon Paul Jenner , View ORCID Profile Viliam Volko , Adam Polak , View ORCID Profile Lubica Fialova , Tomas Augustin , View ORCID Profile Jozef Hanes , Aneta Kozelekova , View ORCID Profile Radek Crha , Lucia Ilkovicova , Rostislav Skrabana , View ORCID Profile Pavel Kaderavek , View ORCID Profile Petr Kolenko , View ORCID Profile Tomas Smolek , View ORCID Profile Eva Kontsekova , View ORCID Profile Branislav Kovacech , View ORCID Profile Jozef Hritz , View ORCID Profile Ondrej Cehlar doi: https://doi.org/10.64898/2026.09.01.748351 Stefana Njemoga 1 Institute of Neuroimmunology, Slovak Academy of Sciences; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Stefana Njemoga Leon Paul Jenner 2 CEITEC MUNI, Brno; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Leon Paul Jenner Viliam Volko 3 CEITEC, MUNI, Brno, Czech Republic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Viliam Volko Adam Polak 1 Institute of Neuroimmunology, Slovak Academy of Sciences; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Lubica Fialova 1 Institute of Neuroimmunology, Slovak Academy of Sciences; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Lubica Fialova Tomas Augustin 1 Institute of Neuroimmunology, Slovak Academy of Sciences; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jozef Hanes 1 Institute of Neuroimmunology, Slovak Academy of Sciences; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Jozef Hanes Aneta Kozelekova 4 CEITEC, MUNI, Brno. Czech Republic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Radek Crha 4 CEITEC, MUNI, Brno. Czech Republic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Radek Crha Lucia Ilkovicova 3 CEITEC, MUNI, Brno, Czech Republic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Rostislav Skrabana 5 Institute of Neuroimmunology; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Pavel Kaderavek 6 CEITEC, MUNI; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Pavel Kaderavek Petr Kolenko 7 Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Petr Kolenko Tomas Smolek 5 Institute of Neuroimmunology; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Tomas Smolek Eva Kontsekova 5 Institute of Neuroimmunology; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Eva Kontsekova Branislav Kovacech 5 Institute of Neuroimmunology; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Branislav Kovacech Jozef Hritz 6 CEITEC, MUNI; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Jozef Hritz Ondrej Cehlar 1 Institute of Neuroimmunology, Slovak Academy of Sciences; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ondrej Cehlar For correspondence: ondrej.cehlar{at}savba.sk Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Conformational antibody DC11 was previously shown to discriminate between physiological full length tau proteins and misfolded truncated tau proteins. It was also shown to catalyze in vitro tau aggregation, suggesting a connection with the pre-aggregation conformation of tau proteins. We have crystallized the Fab fragment of the DC11 antibody and characterized its binding with truncated tau proteins using ELISA, NMR and crosslinking mass spectrometry. The presumed model of the complex of DC11 antibody and truncated tau protein was obtained by docking tau321-391 conformations from coarse grained MD simulation into the antibody paratope. Competing Interest Statement The authors have declared no competing interest. Footnotes https://www.rcsb.org/structure/9H8H Funder Information Declared EU NextGenerationEU , 09I03-03-V04-00623 The Scientific Grant Agency of the Ministry of Education, Research, Development and Youth of the Slovak Republic and the Slovak Academy of Sciences (VEGA) , 2/0125/23 , 1/0825/25 European Union’s Horizon Europe , 101087124 iNEXT Discovery Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . Back to top Previous Next Posted September 02, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Structure and epitope mapping of the conformational anti tau antibody DC11 Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Structure and epitope mapping of the conformational anti tau antibody DC11 Stefana Njemoga , Leon Paul Jenner , Viliam Volko , Adam Polak , Lubica Fialova , Tomas Augustin , Jozef Hanes , Aneta Kozelekova , Radek Crha , Lucia Ilkovicova , Rostislav Skrabana , Pavel Kaderavek , Petr Kolenko , Tomas Smolek , Eva Kontsekova , Branislav Kovacech , Jozef Hritz , Ondrej Cehlar bioRxiv 2026.09.01.748351; doi: https://doi.org/10.64898/2026.09.01.748351 Share This Article: Copy Citation Tools Structure and epitope mapping of the conformational anti tau antibody DC11 Stefana Njemoga , Leon Paul Jenner , Viliam Volko , Adam Polak , Lubica Fialova , Tomas Augustin , Jozef Hanes , Aneta Kozelekova , Radek Crha , Lucia Ilkovicova , Rostislav Skrabana , Pavel Kaderavek , Petr Kolenko , Tomas Smolek , Eva Kontsekova , Branislav Kovacech , Jozef Hritz , Ondrej Cehlar bioRxiv 2026.09.01.748351; doi: https://doi.org/10.64898/2026.09.01.748351 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Animal Behavior and Cognition (7953) Biochemistry (18602) Bioengineering (14744) Bioinformatics (44050) Biophysics (22431) Cancer Biology (19557) Cell Biology (26708) Clinical Trials (138) Developmental Biology (13874) Ecology (20842) Epidemiology (2067) Evolutionary Biology (25267) Genetics (16084) Genomics (23365) Immunology (18560) Microbiology (42156) Molecular Biology (17924) Neuroscience (92702) Paleontology (693) Pathology (2964) Pharmacology and Toxicology (5054) Physiology (8040) Plant Biology (15881) Scientific Communication and Education (2090) Synthetic Biology (4532) Systems Biology (10168) Zoology (2371)
## Related Clinical Research

- [Correction: Data-driven framework for modeling the dendritic spine continuum — funding and corresp](https://medichelpline.com/clinical-feed/plos-one-1-correction-a-data-driven-framework-for-modeling-the-dendritic-spine-continuum.md)
- [Serum Na–Cl Difference as a Noninvasive Screen for CO2 Retention in ALS](https://medichelpline.com/clinical-feed/plos-one-2-serum-na-cl-value-from-routine-blood-tests-reflects-co-2-retention-in.md)
- [Periodised Power Training (POWER) Pilot RCT Protocol for Chronic Stroke Recovery](https://medichelpline.com/clinical-feed/bmj-open-9-periodised-power-training-in-community-dwelling-adults-with-chronic-stroke-a.md)
- [Night-onset Stroke Linked to Worse 3‑Month Outcomes After Reperfusion Therapy](https://medichelpline.com/clinical-feed/bmj-open-19-association-of-time-of-day-at-stroke-onset-with-functional-outcomes-after.md)
- [Excitatory progenitor diversification in the rhombic lip drives evolution of new cerebellar nuclei](https://medichelpline.com/clinical-feed/biorxiv-18-evolution-of-new-cerebellar-nuclei-by-excitatory-progenitor-diversification-in.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.